- Home
- HNRG vs URGN Comparison
HNRG vs URGN Comparison
Compare HNRG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- URGN
- Stock Information
- Founded
- HNRG 1949
- URGN 2004
- Country
- HNRG United States
- URGN United States
- Employees
- HNRG N/A
- URGN N/A
- Industry
- HNRG Coal Mining
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- URGN Health Care
- Exchange
- HNRG Nasdaq
- URGN Nasdaq
- Market Cap
- HNRG 551.9M
- URGN 465.9M
- IPO Year
- HNRG N/A
- URGN 2017
- Fundamental
- Price
- HNRG $10.99
- URGN $10.08
- Analyst Decision
- HNRG Strong Buy
- URGN Strong Buy
- Analyst Count
- HNRG 2
- URGN 6
- Target Price
- HNRG $15.00
- URGN $42.25
- AVG Volume (30 Days)
- HNRG 465.3K
- URGN 308.1K
- Earning Date
- HNRG 03-12-2025
- URGN 03-13-2025
- Dividend Yield
- HNRG N/A
- URGN N/A
- EPS Growth
- HNRG N/A
- URGN N/A
- EPS
- HNRG N/A
- URGN N/A
- Revenue
- HNRG $429,359,000.00
- URGN $89,363,000.00
- Revenue This Year
- HNRG N/A
- URGN $12.17
- Revenue Next Year
- HNRG $7.22
- URGN $44.23
- P/E Ratio
- HNRG N/A
- URGN N/A
- Revenue Growth
- HNRG N/A
- URGN 15.64
- 52 Week Low
- HNRG $4.33
- URGN $9.78
- 52 Week High
- HNRG $14.00
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- HNRG 46.83
- URGN 40.55
- Support Level
- HNRG $10.80
- URGN $9.86
- Resistance Level
- HNRG $11.50
- URGN $11.87
- Average True Range (ATR)
- HNRG 0.60
- URGN 0.50
- MACD
- HNRG 0.08
- URGN -0.04
- Stochastic Oscillator
- HNRG 38.57
- URGN 10.95
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.